Navigation Links
PTC Therapeutics to Present at World Muscle Society Congress
Date:9/25/2013

SOUTH PLAINFIELD, N.J., Sept. 25, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that four posters will be presented at the 18th International World Muscle Society Congress (WMS) in Asilomar, California, on October 1-5. The following posters will be presented on October 3 from 14:30 - 16:00 during Dystrophinopathy pharmco and pharmaco-gene therapy Session.

  • Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne muscular dystrophy - results of a post-hoc analysis of change in %-predicted 6-minute walk distance;
  • Design of a confirmatory phase 3, multicenter, randomized, double-blind, placebo-controlled study of ataluren in patients with nonsense mutation Duchenne muscular dystrophy

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

In addition, Craig McDonald, M.D., one of the world's leading experts in muscular dystrophy clinical endpoints and DMD natural history studies, will present two posters on data obtained from ataluren's Phase 2b study in patients with nonsense mutation Duchenne muscular dystrophy.

  • The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study;
  • The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study

About PTC Therapeutics, Inc.
PTC is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. While PTC's discovery programs are directed at targets in multiple therapeutic areas, PTC is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. For more information on the company, please visit our website www.ptcbio.com.

Forward Looking Statements:
Any statements in this press release about future expectations, plans and prospects for the Company, the development of and potential market for the Company's product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" section of the final prospectus for our initial public offering, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.

 

 

 


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
2. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
3. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
4. Cell Therapeutics Announces Closing of Sale of Convertible Preferred Stock
5. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
6. Cell Therapeutics Announces Sale of Convertible Preferred Stock
7. BGI Tech and South Texas Accelerated Research Therapeutics Initiate Collaboration to Advance Unique San Antonio 1000 Cancer Genome Project
8. Breckenridge Completes Acquisition of Certain Cypress Products from Pernix Therapeutics
9. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
10. Sorrento Therapeutics Completes IgDraSol Merger
11. MicroConstants China In-licenses Phase 2 Liver Cancer Drug from Canadian Pertinax Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... Getting enough sleep affects much more than energy – it also has mental and physical ... compromise motor reaction time, which can increase the risk of having a car accident. ... from the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... California (PRWEB) , ... April 28, 2017 , ... ... T8 Direct Replace tubes . These lamps offer an instant energy-saving solution for ... need to rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
(Date:4/28/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a new ... not. Yisrayl says with so many titles and names for the Creator, it’s hard ... a little Scripture, backed with a lot of research, the truth is undeniable. , ...
Breaking Medicine News(10 mins):